Taiwan
· Delayed Price · Currency is TWD OBI Pharma Statistics
Total Valuation
OBI Pharma has a market cap or net worth of TWD 15.66 billion. The enterprise value is 15.41 billion.
| Market Cap | 15.66B |
| Enterprise Value | 15.41B |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OBI Pharma has 229.25 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Shares Outstanding | 229.25M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 6.33% |
| Float | 166.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 269.65 |
| PB Ratio | 5.45 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.15 |
| EV / Sales | 265.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.71 |
Financial Position
The company has a current ratio of 15.84, with a Debt / Equity ratio of 0.13.
| Current Ratio | 15.84 |
| Quick Ratio | 13.87 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.25 |
| Interest Coverage | -198.17 |
Financial Efficiency
Return on equity (ROE) is -46.55% and return on invested capital (ROIC) is -25.70%.
| Return on Equity (ROE) | -46.55% |
| Return on Assets (ROA) | -25.39% |
| Return on Capital (ROIC) | -25.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | 4.45 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.48% in the last 52 weeks. The beta is 0.90, so OBI Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -16.48% |
| 50-Day Moving Average | 75.80 |
| 200-Day Moving Average | 67.18 |
| Relative Strength Index (RSI) | 37.99 |
| Average Volume (20 Days) | 1,982,910 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OBI Pharma had revenue of TWD 58.05 million and -2.16 billion in losses. Loss per share was -9.41.
| Revenue | 58.05M |
| Gross Profit | -75.76M |
| Operating Income | -2.22B |
| Pretax Income | -2.34B |
| Net Income | -2.16B |
| EBITDA | -2.06B |
| EBIT | -2.22B |
| Loss Per Share | -9.41 |
Balance Sheet
The company has 1.84 billion in cash and 503.62 million in debt, giving a net cash position of 1.34 billion or 5.84 per share.
| Cash & Cash Equivalents | 1.84B |
| Total Debt | 503.62M |
| Net Cash | 1.34B |
| Net Cash Per Share | 5.84 |
| Equity (Book Value) | 3.96B |
| Book Value Per Share | 12.52 |
| Working Capital | 2.00B |
Cash Flow
In the last 12 months, operating cash flow was -1.86 billion and capital expenditures -133.58 million, giving a free cash flow of -2.00 billion.
| Operating Cash Flow | -1.86B |
| Capital Expenditures | -133.58M |
| Free Cash Flow | -2.00B |
| FCF Per Share | -8.72 |
Margins
| Gross Margin | -130.51% |
| Operating Margin | -3,825.37% |
| Pretax Margin | -4,034.76% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -3,442.65% |
Dividends & Yields
OBI Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | -0.02% |
| Earnings Yield | -13.77% |
| FCF Yield | -12.76% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OBI Pharma has an Altman Z-Score of 14.67.
| Altman Z-Score | 14.67 |
| Piotroski F-Score | n/a |